内镜下食管静脉曲张套扎术与普萘洛尔用于肝细胞癌患者食管静脉曲张出血一级预防的开放标签、两中心随机对照试验
这项开放标签、两中心随机对照试验将144例无既往食管静脉曲张出血史的肝细胞癌合并中大型食管静脉曲张患者按1:1随机分配至内镜下食管静脉曲张套扎术(EVL)组(n=72)或普萘洛尔(PPL)组(n=72)。EVL组7例发生食管静脉曲张出血、30例死亡,PPL组19例发生出血、40例死亡;EVL组食管静脉曲张出血累积发生率低于PPL组(Gray检验 p=0.009),两组死亡率无差异(Gray检验 p=0.085)。结论认为EVL在预防初始食管静脉曲张出血方面优于PPL,对出血和总生存的获益可能仅限于BCLC A/B期患者。
要点
- EVL组食管静脉曲张出血累积发生率低于PPL组(Gray检验 p=0.009),两组死亡率无差异(p=0.085)。
- BCLC A/B期患者中EVL在减少出血(p<0.001)和死亡(p=0.003)方面优于PPL。
- BCLC B期以上患者两组结局相似,其他上消化道出血、非出血性肝失代偿及不良事件无组间差异。
核心结论
- EVL在预防肝细胞癌患者初始食管静脉曲张出血方面优于PPL。
- EVL对食管静脉曲张出血和总生存的获益可能仅限于BCLC A/B期患者,而不适用于BCLC C/D期患者。
研究设计与样本
- 开放标签、两中心随机对照试验,2011年6月至2021年4月纳入144例肝细胞癌合并中大型食管静脉曲张且无既往食管静脉曲张出血史的患者,按1:1随机分配至EVL组(n=72)或PPL组(n=72)。
- EVL组每3-4周治疗一次直至静脉曲张根除;PPL组每日剂量至多320 mg。
- 采用竞争风险回归分析食管静脉曲张出血、其他上消化道出血、非出血性肝失代偿、总生存及不良事件的长期随访数据。
主要发现
- EVL组7例发生食管静脉曲张出血、30例死亡;PPL组19例发生食管静脉曲张出血、40例死亡。
- EVL组食管静脉曲张出血累积发生率低于PPL组(Gray检验 p=0.009),两组死亡率无差异(Gray检验 p=0.085)。
- BCLC A/B期患者中,EVL在减少食管静脉曲张出血(p<0.001)和死亡(p=0.003)方面优于PPL。
- BCLC B期以上患者两组结局相似。
- 其他上消化道出血、非出血性肝失代偿及不良事件两组间无差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This randomised trial aimed to address whether endoscopic variceal ligation (EVL) or propranolol (PPL) is more effective at preventing initial oesophageal variceal bleeding (EVB) in patients with hepatocellular carcinoma (HCC). DESIGN: Patients with HCC and medium-to-large oesophageal varices (EVs) but without previous EVB were randomised to receive EVL (every 3-4 weeks until variceal eradication) or PPL (up to 320 mg daily) at a 1:1 ratio. Long-term follow-up data on EVB, other upper gastrointestinal bleeding (UGIB), non-bleeding liver decompensation, overall survival (OS) and adverse events (AEs) were analysed using competing risk regression. RESULTS: Between June 2011 and April 2021, 144 patients were randomised to receive EVL (n=72) or PPL (n=72). In the EVL group, 7 patients experienced EVB, and 30 died; in the PPL group, 19 patients had EVB, and 40 died. The EVL group had a lower cumulative incidence of EVB (Gray's test, p=0.009) than its counterpart, with no mortality difference (Gray's test, p=0.085). For patients with Barcelona Clinic Liver Cancer (BCLC) stage A/B, EVL was better than PPL in reducing EVB (p<0.001) and mortality (p=0.003). For patients beyond BCLC stage B, between-group outcomes were similar. Other UGIB, non-bleeding liver decompensation and AEs did not differ between groups. A competing risk regression model confirmed the prognostic value of EVL. CONCLUSION: EVL is superior to PPL in preventing initial EVB in patients with HCC. The benefits of EVL on EVB and OS may be limited to patients with BCLC stage A/B and not to those with BCLC stage C/D. TRIAL REGISTRATION NUMBER: NCT01970748.
引用
- Yang TC, Chen WC, Hou MC, et al. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial. Gut. 2024. PMID: 38123994. doi:10.1136/gutjnl-2023-330419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。